Eiger Halts Phase 3 LIMT-2 Trial in Hepatitis D
The discontinuation of LIMT-2 was announced after 4 patients experienced hepatobiliary events resulting in liver decompensation during the phase 3 study of peginterferon lambda for HDV.
Source: hcplive.com